Major Depressive Disorder Clinical Trial
Official title:
Emotional Brain Networks & Cognitive Functioning in Depression and Anxiety
NCT number | NCT03084042 |
Other study ID # | UESTC-neuSCAN-23 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | June 2019 |
This study aims to 1) examine common and specific emotional and cognitive dysfunctions between Major Depression and generalized anxiety disorder; 2) Examine emotional and cognitive dysfunctions between the two disorders and healthy controls; 3) Examine the biomarkers predicting successful therapy or not.
Status | Recruiting |
Enrollment | 105 |
Est. completion date | June 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - GAD: 1. Diagnosis of Generalized Anxiety Disorder (GAD) according to DSM V criteria in a structured clinical interview for DSM-V Axis I disorders (SCID I; APA, 2014) and a confirmatory clinical interview 2. Duration of the current episode > 3 weeks - MDD: 1. Diagnosis of current major depressive disorder in a structured clinical interview for DSM-V Axis I disorders (SCID I; APA, 2014) and a confirmatory clinical interview 2. Duration of the current episode > 4 weeks Exclusion Criteria: - GAD: diagnosis of any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months - MDD: diagnosis of any other psychiatric Axis I disorder (except MDD) as a principal diagnosis within the past six months |
Country | Name | City | State |
---|---|---|---|
China | School of Life Science and Technology, University of Electronic Science and Technology of China | Chendu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
University of Electronic Science and Technology of China | Sichuan Provincial People's Hospital, The Fourth People's Hospital of Chengdu |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI | fMRI based indices during emotional face processing | 1 hour (assessed at study inclusion) | |
Primary | Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI | fMRI based indices during empathy processing | 1 hour (assessed at study inclusion) | |
Primary | Brain activity in the emotional and cognitive core regions of the brain as assessed by fMRI | fMRI based indices during working memory | 1 hour (assessed at study inclusion) | |
Secondary | Behavioral performance during the fMRI: face processing | Accuracy during face processing | 1 hour (assessed at study inclusion) | |
Secondary | Behavioral performance during the fMRI: empathy reactivity | Empathy in response to empathy inducing pictures (rated on Likert scale) | 1 hour (assessed at study inclusion) | |
Secondary | Behavioral performance during the fMRI: working memory | Working memory performance during fMRI | 1 hour (assessed at study inclusion) | |
Secondary | Cognitive performance at study inclusion | Executive functions as assessed via computerized tests (CANTAB) | 1 hour (assessed at study inclusion) | |
Secondary | Symptom improvement after 3 months: depression | Symptoms of depression will be assessed using validated clinical scales (e.g. BDI) | 3 months | |
Secondary | Symptom improvement after 3 months: anxiety | Symptoms of generalized anxiety will be assessed using validated clinical scales (e.g. Penn State Worry Questionnaire) | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |